+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cephalosporin Market: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

  • ID: 4828948
  • Report
  • March 2019
  • Region: Global
  • 239 pages
  • Allied Analytics LLP
1 of 4
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics that is majorly used to treat bacterial infections. It resembles penicillin and hence, is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea.
The major factors that contribute to the growth of the cephalosporin market include increase in R&D activities to develop highly efficient & safe drugs, upsurge in use of combination therapies, and rise in prevalence of pneumonia, tonsillitis, bronchitis, and gonorrhea. Moreover, increased approvals of drugs and growth in awareness about various infections & antibiotic resistance propel the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains impede the market growth. Conversely, increase in mergers and acquisition among key vendors and development of combination therapies in the untapped market are anticipated to provide potential opportunities for the market growth.
The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. Based on generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generics. Depending on route of drug administration, it is classified into injection and oral. The applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • The report provides an in-depth analysis of market trends, macro-economic indicators, and governing factors.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the market through 2017–2025 that helps identify the upcoming market opportunities.
  • Recent industry trends and developments and the future opportunities are also covered.
  • Extensive knowledge about the key market players and their strategies is provided.
  • Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.
Key Market Segments
  • By Generation
o First-generation Cephalosporin
o Second-generation Cephalosporin
o Third-generation Cephalosporin
o Fourth-generation Cephalosporin
o Fifth-generation Cephalosporin
  • By Type
o Branded
o Generics
  • By Route of Drug Administration
o Injection
o Oral
  • By Application
o Respiratory Tract Infection
o Skin Infection
o Ear Infection
o Urinary Tract Infection
o Sexually Transmitted Infection
o Others
  • By Region
o North America
  • U.S.
  • Canada
  • Mexico
o Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Rest of Europe
o Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
o LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
Key market players

The key players operating in this market include
  • Allergan Plc
  • Bristol-Myers Squibb Company
  • Lupin Limited
  • Sanofi
  • Novartis International AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
2 of 4
Chapter 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key Findings
3.2.1. Top investment pockets
3.3. Top winning strategies
3.3.1. Top Winning Strategies, by year, 2015-2018*
3.3.2. Top Winning Strategies, by development, 2015-2018* (%)
3.3.3. Top Winning Strategies, by company, 2015-2018*
3.3.4. Market Dynamics
3.3.5. Drivers
3.3.5.1. Surge in incidence of infectious diseases
3.3.5.2. Increase in R&D activities for the development of combination drugs
3.3.5.3. Rise in funding for the development of antibiotics
3.3.6. Restraints
3.3.6.1. Side effects associated with cephalosporin
3.3.6.2. Antibiotic resistance to cephalosporin
3.3.7. Opportunities
3.3.7.1. Lucrative opportunities in the emerging economies
3.4. Market Share Analysis, 2017
3.5. Porter’s Five Forces Analysis
3.6. Novel Molecules in Cephalosporin Market
3.6.1. Ceftazidime
3.6.2. Cefuroxime
3.7. Combination Therapies in Cephalosporin Market

Chapter 4: CEPHALOSPORIN MARKET, BY GENERATION
4.1. Overview
4.1.1. Market size and forecast
4.2. First-Generation Cephalosporin
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. Second-Generation Cephalosporin
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. Third-Generation Cephalosporin
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. Fourth-Generation Cephalosporin
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. Fifth-Generation Cephalosporin
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

Chapter 5: CEPHALOSPORIN MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Branded Cephalosporin drugs
5.2.1. Market size and forecast
5.3. Generic Cephalosporin Drugs
5.3.1. Market size and forecast

Chapter 6: CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cephaloshorin Injections
6.2.1. Market size and forecast
6.3. Oral Cephalosporin Drugs
6.3.1. Market size and forecast

Chapter 7: CEPHALOSPORIN MARKET, BY APPLICATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Respiratory Tract Infection
7.2.1. Market size and forecast
7.3. Skin Infection
7.3.1. Market size and forecast
7.4. Ear Infection
7.4.1. Market size and forecast
7.5. Urinary Tract Infection
7.5.1. Market size and forecast
7.6. Sexually Transmitted Infection
7.6.1. Market size and forecast
7.7. Others
7.7.1. Market size and forecast

Chapter 8: CEPHALOSPORIN MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends
8.2.2. Growth factors and opportunities
8.2.3. North America cephalosporin market by country
8.2.3.1. U.S.
8.2.3.1.1. U.S. cephalosporin market by generation
8.2.3.1.2. U.S. cephalosporin market by type
8.2.3.1.3. U.S. cephalosporin market by route of drug administration
8.2.3.1.4. U.S. cephalosporin market by application
8.2.3.2. Canada
8.2.3.2.1. Canada cephalosporin market by generation
8.2.3.2.2. Canada cephalosporin market by type
8.2.3.2.3. Canada cephalosporin market by route of drug administration
8.2.3.2.4. Canada cephalosporin market by application
8.2.3.3. Mexico
8.2.3.3.1. Mexico cephalosporin market by generation
8.2.3.3.2. Mexico cephalosporin market by type
8.2.3.3.3. Mexico cephalosporin market by route of drug administration
8.2.3.3.4. Mexico cephalosporin market by application
8.2.4. North America cephalosporin market by generation
8.2.5. North America cephalosporin market by type
8.2.6. North America cephalosporin market by route of drug administration
8.2.7. North America cephalosporin market by application
8.3. Europe
8.3.1. Key market trends
8.3.2. Growth factors and opportunities
8.3.3. Europe cephalosporin market by country
8.3.3.1. Germany
8.3.3.1.1. Germany cephalosporin market by generation
8.3.3.1.2. Germany cephalosporin market by type
8.3.3.1.3. Germany cephalosporin market by route of drug administration
8.3.3.1.4. Germany cephalosporin market by application
8.3.3.2. France
8.3.3.2.1. France cephalosporin market by generation
8.3.3.2.2. France cephalosporin market by type
8.3.3.2.3. France cephalosporin market by route of drug administration
8.3.3.2.4. France cephalosporin market by application
8.3.3.3. UK
8.3.3.3.1. UK cephalosporin market by generation
8.3.3.3.2. UK cephalosporin market by type
8.3.3.3.3. UK cephalosporin market by route of drug administration
8.3.3.3.4. UK cephalosporin market by application
8.3.3.4. Italy
8.3.3.4.1. Italy cephalosporin market by generation
8.3.3.4.2. Italy cephalosporin market by type
8.3.3.4.3. Italy cephalosporin market by route of drug administration
8.3.3.4.4. Italy cephalosporin market by application
8.3.3.5. Spain
8.3.3.5.1. Spain cephalosporin market by generation
8.3.3.5.2. Spain cephalosporin market by type
8.3.3.5.3. Spain cephalosporin market by route of drug administration
8.3.3.5.4. Spain cephalosporin market by application
8.3.3.6. Rest of Europe
8.3.3.6.1. Rest of Europe cephalosporin market by generation
8.3.3.6.2. Rest of Europe cephalosporin market by type
8.3.3.6.3. Rest of Europe cephalosporin market by route of drug administration
8.3.3.6.4. Rest of Europe cephalosporin market by application
8.3.4. Europe cephalosporin market by generation
8.3.5. Europe cephalosporin market by type
8.3.6. Europe cephalosporin market by route of drug administration
8.3.7. Europe cephalosporin market by application
8.4. ASIA-PACIFIC
8.4.1. Key market trends
8.4.2. Growth factors and opportunities
8.4.3. Asia-Pacific cephalosporin market by country
8.4.3.1. Japan
8.4.3.1.1. Japan cephalosporin market by generation
8.4.3.1.2. Japan cephalosporin market by type
8.4.3.1.3. Japan cephalosporin market by route of drug administration
8.4.3.1.4. Japan cephalosporin market by application
8.4.3.2. China
8.4.3.2.1. China cephalosporin market by generation
8.4.3.2.2. China cephalosporin market by type
8.4.3.2.3. China cephalosporin market by route of drug administration
8.4.3.2.4. China cephalosporin market by application
8.4.3.3. India
8.4.3.3.1. India cephalosporin market by generation
8.4.3.3.2. India cephalosporin market by type
8.4.3.3.3. India cephalosporin market by route of drug administration
8.4.3.3.4. India cephalosporin market by application
8.4.3.4. Australia
8.4.3.4.1. Australia cephalosporin market by generation
8.4.3.4.2. Australia cephalosporin market by type
8.4.3.4.3. Australia cephalosporin market by route of drug administration
8.4.3.4.4. Australia cephalosporin market by application
8.4.3.5. South Korea
8.4.3.5.1. South Korea cephalosporin market by generation
8.4.3.5.2. South Korea cephalosporin market by type
8.4.3.5.3. South Korea cephalosporin market by route of drug administration
8.4.3.5.4. South Korea cephalosporin market by application
8.4.3.6. Rest of Asia-Pacific
8.4.3.6.1. Rest of Asia-Pacific cephalosporin market by generation
8.4.3.6.2. Rest of Asia-Pacific cephalosporin market by type
8.4.3.6.3. Rest of Asia-Pacific cephalosporin market by route of drug administration
8.4.3.6.4. Rest of Asia-Pacific cephalosporin market by application
8.4.4. Asia-Pacific cephalosporin market by generation
8.4.5. Asia-Pacific cephalosporin market by type
8.4.6. Asia-Pacific cephalosporin market by route of drug administration
8.4.7. Asia-Pacific cephalosporin market by application
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Growth factors and opportunities
8.5.3. LAMEA cephalosporin market by country
8.5.3.1. Brazil
8.5.3.1.1. Brazil cephalosporin market by generation
8.5.3.1.2. Brazil cephalosporin market by type
8.5.3.1.3. Brazil cephalosporin market by route of drug administration
8.5.3.1.4. Brazil cephalosporin market by application
8.5.3.2. South Africa
8.5.3.2.1. South Africa cephalosporin market by generation
8.5.3.2.2. South Africa cephalosporin market by type
8.5.3.2.3. South Africa cephalosporin market by route of drug administration
8.5.3.2.4. South Africa cephalosporin market by application
8.5.3.3. Saudi Arabia
8.5.3.3.1. Saudi Arabia cephalosporin market by generation
8.5.3.3.2. Saudi Arabia cephalosporin market by type
8.5.3.3.3. Saudi Arabia cephalosporin market by route of drug administration
8.5.3.3.4. Saudi Arabia cephalosporin market by application
8.5.3.4. Rest of LAMEA
8.5.3.4.1. Rest of LAMEA cephalosporin market by generation
8.5.3.4.2. Rest of LAMEA cephalosporin market by type
8.5.3.4.3. Rest of LAMEA cephalosporin market by route of drug administration
8.5.3.4.4. Rest of LAMEA cephalosporin market by application
8.5.4. LAMEA cephalosporin market by generation
8.5.5. LAMEA cephalosporin market by type
8.5.6. LAMEA cephalosporin market by route of drug administration
8.5.7. LAMEA cephalosporin market by application

Chapter 9: COMPANY PROFILES
9.1. Allergan Plc.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments
9.2. Bristol-Myers Squibb Company
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segment
9.2.4. Product portfolio
9.2.5. Business performance
9.3. F. Hoffmann-La Roche Ltd.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. GlaxoSmithKline plc
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. Lupin Limited (Lupin Pharmaceuticals, Inc.)
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. Merck & Co. Inc.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments
9.7. Novartis International AG (Sandoz)
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.8. Pfizer Inc.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Sanofi
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. Teva Pharmaceutical Industries Ltd.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled, 'Cephalosporin Market by Generation, Type, Route of Drug Administration, and Application: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,' the global cephalosporin market size was valued at $11,869 million in 2017, and is estimated to reach $14,022 million by 2025, growing at a CAGR of 2.0% from 2018 to 2025. The third-generation cephalosporin segment held more than 30% of the total cephalosporin market share in 2017.

Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. The major factors contributing to the growth of the market include increase in incidence of population suffering from pneumonia, tonsillitis, bronchitis, and gonorrhea. In addition, increase in R&D activities to develop highly efficient & safe drugs and upsurge in use of combination therapies further boost the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains restrain the market growth.

Based on application, the market is segmented into respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. The respiratory tract infection segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period, as cephalosporin are used for treatment of both upper & lower respiratory tract infection and lower respiratory infections are the leading infectious causes of death globally. Hence, oral cephalosporin is used in the treatment of lower and upper respiratory tract infections widely. However, the sexually transmitted infection is expected to register highest CAGR during the forecast period, due to the rising rate of sexually transmitted infections globally and some second-generation cephalosporin and most of the third-generation cephalosporin are effective in the treatment.

Based on generation, the market is classified into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. The third-generation cephalosporin segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period, as these have a broader spectrum of activity and these are used for the treatment of Gram-negative bacillary meningitis, serious infections of enterobacteriaceae, otitis media, and others. However, the fifth-generation cephalosporin is expected to register highest CAGR of 3.3% during the forecast period.

Based on region, the antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2017, accounting for the highest share, and is anticipated to maintain cephalosporin market trends throughout the forecast period. This is attributed to increased consumption of cephalosporin, its easy availability, and rise in sale of over-the-counter drugs, and increase in bacterial infection in the region. LAMEA is projected to register the highest CAGR of 4.2% during the forecast period, owing to increase in incidence of infectious diseases. In addition, rise in healthcare expenditure is anticipated to offer a lucrative opportunity for the market growth.

Key Findings of the Cephalosporin Market:

Branded cephalosporin segment is expected to register the highest CAGR of 2.3% during the analysis period.
Based on route of drug administration, the injectable cephalosporin segment accounted for the largest share in 2017 and is expected to maintain its dominance during the forecast period.
India and China collectively contributed for more than 40% share of the Asia-Pacific cephalosporin market in 2017.
U.S. was the major shareholder that accounted for more than 90% of the North America cephalosporin market in 2017.

The report provides a comprehensive analysis of the key players operating in the global cephalosporin industry, Allergan Plc., Bristol-Myers Squibb Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Limited (Lupin Pharmaceuticals, Inc.), Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Eli Lilly and Company, Bayer HealthCare, Sun Pharmaceutical, Shionogi, and others.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll